DHW-221

CAS No.：2378831-21-9
Grade：99.98%
Formula：C27H22F2N4O5S
M.W.：552.55

Important Notice

This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.

View the full Disclaimer

Overview

DHW-221 is a potent orally active dual PI3K/mTOR inhibitor, exhibiting low nanomolar potency against all four Class I PI3K isoforms and mTOR ( PI3Kα , IC 50 = 0.50 nM; PI3Kβ , IC 50 = 1.9 nM; PI3Kγ , IC 50 = 1.8 nM; PI3Kδ , IC 50 = 0.74 nM; mTOR , IC 50 = 3.9 nM). DHW-221 exerts antitumor effects by blocking the PI3K/Akt/mTOR pathway and inducing mitochondrial apoptosis and paraptosis (via Endoplasmic Reticulum (ER) stress and MAPK signaling) and arrests cell cycle, thereby inhibiting cell migration, invasion and angiogenesis. DHW-221 inhibits tumor growth in both the A549/Taxol ( HY-B0015 ) and the HCC827 xenograft mouse models. DHW-221 can be used for non-small cell lung cancer (NSCLC), colon and breast cancer research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Paraptosis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Mitochondrial Metabolism | Products > Signaling Pathways > P-glycoprotein | Products > Signaling Pathways > CDK | Products > Signaling Pathways > MMP | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > PI3K

Product Information

Catalog No.: HY-130133
CAS No.: 2378831-21-9
Molecular Formula: C27H22F2N4O5S
Molecular Weight: 552.55
Purity: 99.98%
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source

Welcome！

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
+86-23-6139-8061 +86-13650506873
danny@chemdad.com sales@chemdad.com
www.chemdad.com
WhatsApp +86-13650506873